FDA Recalls Oxytocin IV Bags for Sterility Assurance Issues
Central Admixture Pharmacy Services recalls 1,937 bags of oxytocin 10 units in Lactated Ringer's IV bags nationwide due to insufficient sterility assurance and missing validation data for decontamination cycles.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a critical injectable medication. The hazard—lack of sterility assurance in an intravenous product—represents a risk-of-harm scenario, and the source documentation contains no reports of injury, meeting the criterion for High severity.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 1,937 bags of oxytocin 10 units added to Lactated Ringer's 500 mL IV bags (NDC 72196-6036-1) due to insufficient assurance of product sterility. The affected product was distributed nationwide across the United States.
The recall stems from a lack of assurance of sterility and missing validation data for decontamination cycles used in the manufacturing process. Oxytocin is a potent medication used in obstetric and gynecologic applications, and sterility is critical for intravenous medications.
The recall affects the following lot numbers and expiration dates: Lot 36-246733 (Exp. 7/12/2023); Lots 36-247777 and 36-247779 (Exp. 7/15/2023); Lot 36-250334 (Exp. 7/29/2023); Lots 36-251383 and 36-251384 (Exp. 8/2/2023); and Lot 36-251990 (Exp. 8/5/2023). Healthcare facilities and practitioners with this product should immediately quarantine it and contact Central Admixture Pharmacy Services for return instructions. Do not administer affected product to patients.
The recalled product
- Product
- oxyTOCIN 10 units added to Lactated Ringer's 500 mL, IV Bag, Rx only, Cental Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-6036-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous Injection
- Hazard
- sterility-failure
- inadequate-decontamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lot: 36-246733
- Exp. 7/12/2023
- 36-247777
- 36-247779
- Exp. 7/15/2023
- 36-250334
- Exp. 7/29/2023
- 36-251383
- 36-251384
- Exp. 8/2/2023
- 36-251990
- Exp. 8/5/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27